Melatonin inhibits the proliferation of human osteosarcoma cell line MG-63

Lifeng Liu, Ying Xu, Russel J Reiter

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

It seems established that the onset of osteosarcoma and the reduction in melatonin production run in parallel; this suggests that the decline in the cancer-inhibiting agent, melatonin, may contribute to the occurrence of osteosarcoma and that melatonin supplementation may have promise for preventing the development and progression of this condition. There is, however, no direct evidence regarding an antiproliferative effect of melatonin in osteosarcoma cells. In the current study, we examined whether melatonin inhibits the proliferation of human osteosarcoma cell line MG-63. MTT staining showed that at 4mM-10mM concentrations, melatonin significantly reduced the MG-63 cell proliferation in a dose-dependent and time-dependent manner. Flow cytometry documented that 4mM melatonin significantly increased the fraction of cells in the G0/G1 phase of the cell cycle, while simultaneously reducing the proportion in the S and G2/M phases. Western blot and real-time PCR analyses further confirmed that melatonin's inhibitory effect was possibly because of downregulation of cyclin D1 and CDK4, related to the G1 phase, and of cyclin B1 and CDK1, related to the G2/M phase. There was no downregulation of cyclin E, CDK2, and cyclin A, which are related to G1/S transition and S phase. These findings provide evidence that melatonin may significantly inhibit human osteosarcoma cell proliferation in a dose-dependent and time-dependent manner and this inhibition involves the downregulation of cyclin D1, CDK4, cyclin B1 and CDK1.

Original languageEnglish (US)
Pages (from-to)432-438
Number of pages7
JournalBone
Volume55
Issue number2
DOIs
StatePublished - Aug 2013

Fingerprint

Osteosarcoma
Melatonin
Cell Line
Cyclin B1
Down-Regulation
G2 Phase
Cyclin D1
G1 Phase
Cell Division
Cell Proliferation
Cyclin A
Cyclin E
Cell Cycle Resting Phase
S Phase
Real-Time Polymerase Chain Reaction
Cell Cycle
Flow Cytometry
Western Blotting
Staining and Labeling

Keywords

  • Cell cycle
  • Melatonin
  • MG-63
  • Osteosarcoma
  • Proliferation

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Melatonin inhibits the proliferation of human osteosarcoma cell line MG-63. / Liu, Lifeng; Xu, Ying; Reiter, Russel J.

In: Bone, Vol. 55, No. 2, 08.2013, p. 432-438.

Research output: Contribution to journalArticle

Liu, Lifeng ; Xu, Ying ; Reiter, Russel J. / Melatonin inhibits the proliferation of human osteosarcoma cell line MG-63. In: Bone. 2013 ; Vol. 55, No. 2. pp. 432-438.
@article{de8c20b6acaa47d0a54ad7b55cf10573,
title = "Melatonin inhibits the proliferation of human osteosarcoma cell line MG-63",
abstract = "It seems established that the onset of osteosarcoma and the reduction in melatonin production run in parallel; this suggests that the decline in the cancer-inhibiting agent, melatonin, may contribute to the occurrence of osteosarcoma and that melatonin supplementation may have promise for preventing the development and progression of this condition. There is, however, no direct evidence regarding an antiproliferative effect of melatonin in osteosarcoma cells. In the current study, we examined whether melatonin inhibits the proliferation of human osteosarcoma cell line MG-63. MTT staining showed that at 4mM-10mM concentrations, melatonin significantly reduced the MG-63 cell proliferation in a dose-dependent and time-dependent manner. Flow cytometry documented that 4mM melatonin significantly increased the fraction of cells in the G0/G1 phase of the cell cycle, while simultaneously reducing the proportion in the S and G2/M phases. Western blot and real-time PCR analyses further confirmed that melatonin's inhibitory effect was possibly because of downregulation of cyclin D1 and CDK4, related to the G1 phase, and of cyclin B1 and CDK1, related to the G2/M phase. There was no downregulation of cyclin E, CDK2, and cyclin A, which are related to G1/S transition and S phase. These findings provide evidence that melatonin may significantly inhibit human osteosarcoma cell proliferation in a dose-dependent and time-dependent manner and this inhibition involves the downregulation of cyclin D1, CDK4, cyclin B1 and CDK1.",
keywords = "Cell cycle, Melatonin, MG-63, Osteosarcoma, Proliferation",
author = "Lifeng Liu and Ying Xu and Reiter, {Russel J}",
year = "2013",
month = "8",
doi = "10.1016/j.bone.2013.02.021",
language = "English (US)",
volume = "55",
pages = "432--438",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Melatonin inhibits the proliferation of human osteosarcoma cell line MG-63

AU - Liu, Lifeng

AU - Xu, Ying

AU - Reiter, Russel J

PY - 2013/8

Y1 - 2013/8

N2 - It seems established that the onset of osteosarcoma and the reduction in melatonin production run in parallel; this suggests that the decline in the cancer-inhibiting agent, melatonin, may contribute to the occurrence of osteosarcoma and that melatonin supplementation may have promise for preventing the development and progression of this condition. There is, however, no direct evidence regarding an antiproliferative effect of melatonin in osteosarcoma cells. In the current study, we examined whether melatonin inhibits the proliferation of human osteosarcoma cell line MG-63. MTT staining showed that at 4mM-10mM concentrations, melatonin significantly reduced the MG-63 cell proliferation in a dose-dependent and time-dependent manner. Flow cytometry documented that 4mM melatonin significantly increased the fraction of cells in the G0/G1 phase of the cell cycle, while simultaneously reducing the proportion in the S and G2/M phases. Western blot and real-time PCR analyses further confirmed that melatonin's inhibitory effect was possibly because of downregulation of cyclin D1 and CDK4, related to the G1 phase, and of cyclin B1 and CDK1, related to the G2/M phase. There was no downregulation of cyclin E, CDK2, and cyclin A, which are related to G1/S transition and S phase. These findings provide evidence that melatonin may significantly inhibit human osteosarcoma cell proliferation in a dose-dependent and time-dependent manner and this inhibition involves the downregulation of cyclin D1, CDK4, cyclin B1 and CDK1.

AB - It seems established that the onset of osteosarcoma and the reduction in melatonin production run in parallel; this suggests that the decline in the cancer-inhibiting agent, melatonin, may contribute to the occurrence of osteosarcoma and that melatonin supplementation may have promise for preventing the development and progression of this condition. There is, however, no direct evidence regarding an antiproliferative effect of melatonin in osteosarcoma cells. In the current study, we examined whether melatonin inhibits the proliferation of human osteosarcoma cell line MG-63. MTT staining showed that at 4mM-10mM concentrations, melatonin significantly reduced the MG-63 cell proliferation in a dose-dependent and time-dependent manner. Flow cytometry documented that 4mM melatonin significantly increased the fraction of cells in the G0/G1 phase of the cell cycle, while simultaneously reducing the proportion in the S and G2/M phases. Western blot and real-time PCR analyses further confirmed that melatonin's inhibitory effect was possibly because of downregulation of cyclin D1 and CDK4, related to the G1 phase, and of cyclin B1 and CDK1, related to the G2/M phase. There was no downregulation of cyclin E, CDK2, and cyclin A, which are related to G1/S transition and S phase. These findings provide evidence that melatonin may significantly inhibit human osteosarcoma cell proliferation in a dose-dependent and time-dependent manner and this inhibition involves the downregulation of cyclin D1, CDK4, cyclin B1 and CDK1.

KW - Cell cycle

KW - Melatonin

KW - MG-63

KW - Osteosarcoma

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=84878950558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878950558&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2013.02.021

DO - 10.1016/j.bone.2013.02.021

M3 - Article

VL - 55

SP - 432

EP - 438

JO - Bone

JF - Bone

SN - 8756-3282

IS - 2

ER -